Teva Moves Toward Biogenerics Goal With CoGenesys Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.
You may also be interested in...
HGS First Quarter Results Fair; Bigger News Ahead
Despite others’ setbacks, firm maintains optimism for Phase III lupus drug.
HGS First Quarter Results Fair; Bigger News Ahead
Despite others’ setbacks, firm maintains optimism for Phase III lupus drug.
HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.